Spravato (Esketamine) Treatment
A breakthrough FDA-approved nasal spray for adults with treatment-resistant depression — offering meaningful relief within days, not weeks.
Powered by AdvancedMD — HIPAA-compliant secure patient portal
FDA-Approved
For treatment-resistant depression
Days
Rapid onset vs. weeks for antidepressants
2-Hour
Supervised in-office sessions
REMS
Certified treatment center
FDA-Approved
For treatment-resistant depression
Days
Rapid onset vs. weeks for antidepressants
2-Hour
Supervised in-office sessions
REMS
Certified treatment center
FDA-Approved
Since 2019
2-Hour
Monitored sessions
Rapid Onset
Days vs. weeks
REMS Certified
Supervised treatment
When Antidepressants Haven't Been Enough
Spravato (esketamine) is an FDA-approved nasal spray that works on NMDA receptors — a completely different mechanism than traditional antidepressants that target serotonin or dopamine. This novel approach means it can work for patients who have tried multiple antidepressants without adequate relief.
Many patients experience meaningful improvement within hours to days of their first treatment, compared to the 4–8 weeks typically required for oral antidepressants. Spravato is used alongside a standard oral antidepressant as part of a comprehensive treatment plan.
At Mind Body Health & Wellness, Spravato is administered in our certified clinical setting under the direct supervision of Amy Burchett, PMHNP. Because of its unique properties, patients must remain on-site for at least 2 hours after each dose and cannot drive on the day of treatment.
FDA-Approved
For TRD and MDD-SI
Rapid Relief
Days, not weeks
2-Hour Sessions
Monitored in-office
REMS Certified
Supervised treatment
How Spravato Differs from Antidepressants
- Targets NMDA receptors, not serotonin or dopamine
- Relief often within hours to days vs. 4–8 weeks
- FDA-approved specifically for treatment-resistant cases
- Administered in-office under medical supervision
- Used alongside an oral antidepressant
Important Safety Note
You cannot drive on the day of your Spravato treatment. Please arrange transportation. You will be monitored for at least 2 hours after each session.
FDA-Approved Indications
Treatment-Resistant Depression (TRD)
FDA-approved for adults with major depressive disorder who have not responded adequately to at least two different antidepressant treatments.
MDD with Acute Suicidal Ideation
FDA-approved for adults with major depressive disorder who have active suicidal ideation with intent or plan, requiring rapid symptom reduction.
Anxious Depression
Emerging evidence supports Spravato's effectiveness for patients with major depression accompanied by significant anxiety symptoms.
The Spravato Treatment Process
A structured, supervised process designed for your safety and maximum therapeutic benefit.
Consultation & Evaluation
Amy Burchett, PMHNP will evaluate your history, prior treatments, and current symptoms to determine if Spravato is appropriate for you.
Arrive at Our Office
You'll come to our Martinsville, Indiana office. Arrange a driver — you cannot drive on the day of treatment. Eat a light meal at least 2 hours before your session.
Self-Administer Under Supervision
You'll self-administer the nasal spray under Amy's direct supervision. The medication is delivered in two doses, 5 minutes apart.
2-Hour Monitoring Period
You'll remain in our office for at least 2 hours while we monitor for any side effects such as dissociation or dizziness. Most patients tolerate it well.
Spravato vs. Traditional Antidepressants
| Feature | Spravato | Oral Antidepressants |
|---|---|---|
| Mechanism of action | NMDA receptor antagonist | Serotonin/dopamine reuptake |
| Onset of relief | Hours to days | 4–8 weeks |
| FDA-approved for TRD | Yes | Limited options |
| Administration | In-office, supervised | Self-administered at home |
| Driving restriction | Day of treatment | None typically |
| Suitable for medication-resistant patients | Yes | Limited |
Spravato by the numbers
A New Standard for Treatment-Resistant Depression
2
FDA-approved indications
U.S. Food & Drug Administration
Days
Rapid onset of relief
vs. 4–8 weeks for oral antidepressants
REMS
Certified treatment center
Required for all Spravato providers
Could Spravato Be Right for You?
If you've tried antidepressants without adequate relief, Spravato may offer the breakthrough you've been looking for. Schedule a consultation to find out.
Spravato: Frequently Asked Questions
What is Spravato (esketamine)?
Spravato is an FDA-approved nasal spray containing esketamine, a derivative of ketamine. It works on NMDA receptors in the brain — a different mechanism than traditional antidepressants — and is approved for treatment-resistant depression and MDD with acute suicidal ideation.
How quickly does Spravato work?
Many patients experience meaningful improvement within hours to days of their first treatment. This rapid onset is one of Spravato's key advantages over traditional antidepressants, which typically take 4–8 weeks to show full effect.
How is Spravato administered?
Spravato is self-administered as a nasal spray under the direct supervision of a certified healthcare provider. Sessions take place in our office. You will remain on-site for at least 2 hours after each dose for monitoring.
Can I drive after a Spravato treatment?
No. You cannot drive or operate heavy machinery on the day of your Spravato treatment due to the risk of sedation and dissociation. Please arrange transportation to and from each session.
Is Spravato covered by insurance?
Many insurance plans cover Spravato for FDA-approved indications. As an out-of-network provider, we recommend checking with your insurance carrier. We can provide documentation to support your claim.
What are the side effects of Spravato?
Common side effects include dissociation, dizziness, nausea, sedation, and increased blood pressure. These typically occur during or shortly after the session and resolve within 2 hours. This is why on-site monitoring is required.
Important Safety Information: Spravato (esketamine) CIII nasal spray is a federally controlled substance (CIII) because it contains esketamine, which may be abused or lead to dependence. Spravato is available only through a restricted program called the Spravato REMS. Spravato can cause serious side effects including sedation, dissociation, abuse and misuse, and suicidal thoughts and behaviors. Patients must be monitored by a healthcare provider for at least 2 hours after each dose. Patients cannot drive or operate heavy machinery on the day of treatment. Spravato is not approved as a stand-alone therapy — it must be used with an oral antidepressant. Ask your healthcare provider if Spravato is right for you. Patient results may vary.
Related Services
NeuroStar TMS Therapy
FDA-cleared, non-invasive treatment for treatment-resistant depression. Drug-free, no downtime.
Learn moreTelehealth Psychiatry
Secure video visits for diagnosis, therapy, and medication management from the comfort of home.
Learn moreMedication Management
Personalized psychiatric medication oversight to optimize effectiveness and minimize side effects.
Learn moreTake the Next Step Toward Relief
If antidepressants haven't worked, Spravato may be the answer. Schedule a consultation with Amy Burchett, PMHNP today.
Powered by AdvancedMD — HIPAA-compliant secure patient portal